Heer et al (1998) hypothesised that any possible survival advantage (reported by authors such as Badwe et al (1991) of patients who undergo breast cancer surgery in the luteal phase of the cycle could be due to this difference in serum levels of VEGF found in his study. Here, VEGFA is linked to breast cancer.